Labeling galectin-3 for the assessment of myocardial infarction in rats

EJNMMI Research

Volumn 4, Issue 1, 2014, Pages

  Arias, Teresa ^a,b   Petrov, Artiom ^a   Chen, Jiqiu ^a   de Haas, Hans ^a   Pérez Medina, Carlos ^a,b   Strijkers, Gustav J ^a,c   Hajjar, Roger J ^a   Fayad, Zahi A ^a   Fuster, Valentín ^a,b   Narula, Jagat ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Galectin 3; Molecular imaging; Myocardial infarction; Myocardial remodeling; SPECT

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE; GALECTIN 3; IODINE 123;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREATHING RATE; CLINICAL ASSESSMENT; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOLOGY; IN VIVO STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOACTIVITY; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84919754435     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-014-0075-x     Document Type: Article

References (32)

1. Díez J, González A, López B, Querejeta R: Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease.Nat Clin Pract Cardiovasc Med 2005, 2:209–216.
2. Yaniz-Galende E, Chen J, Chemaly E, Liang L, Hulot J-S, McCollum L, Arias T, Fuster V, Zsebo KM, Hajjar RJ: Stem cell factor gene transfer promotes cardiac repair after myocardial infarction via in situ recruitment and expansion of c-kit + cells.Circ Res 2012, 111:1434–1445.
3. Khush KK, Waters DD: Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials.J Card Fail 2006, 12:664–674.
4. Wynn TA, Ramalingam TR: Mechanisms of fibrosis: therapeutic translation for fibrotic disease.Nat Med 2012, 18:1028–1040.
5. Liu Y-H, D’Ambrosio M, Liao T, Peng H, Rhaleb N-E, Sharma U, André S, Gabius H-J, Carretero OA: N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.Am J Physiol Heart Circ Physiol 2009, 296:H404–H412.
6. Böhm M, Voors AA, Ketelslegers J-M, Schirmer SH, Turgonyi E, Bramlage P, Zannad F: Biomarkers: optimizing treatment guidance in heart failure.Clin Res Cardiol 2011, 100:973–981.
7. Gaggin HK, Januzzi JL: Biomarkers and diagnostics in heart failure.Biochim Biophys Acta 2013, 1832:2442–2450.
8. Hartupee J, Mann DL: Positioning of inflammatory biomarkers in the heart failure landscape.J Cardiovasc Transl Res 2013, 6:485–492.
9. Dumic J, Dabelic S, Flögel M: Galectin-3: an open-ended story.Biochim Biophys Acta 2006, 1760:616–635.
10. Krześlak A, Lipińska A: Galectin-3 as a multifunctional protein.Cell Mol Biol Lett 2004, 9:305–328.
11. De Boer RA, Yu L, van Veldhuisen DJ: Galectin-3 in cardiac remodeling and heart failure.Curr Heart Fail Rep 2010, 7:1–8.
12. De Boer RA, Lok DJA, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ: Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.Ann Med 2011, 43:60–68.
13. Tsai T-H, Sung P-H, Chang L-T, Sun C-K, Yeh K-H, Chung S-Y, Chua S, Chen Y-L, Wu C-J, Chang H-W, Ko S-F, Yip H-K: Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention.J Atheroscler Thromb 2012, 19:1073–1082.
14. Weir RAP, Petrie CJ, Murphy CA, Clements S, Steedman T, Miller AM, McInnes IB, Squire IB, Ng LL, Dargie HJ, McMurray JJV: Galectin-3 and cardiac function in survivors of acute myocardial infarction.Circ Heart Fail 2013, 6:492–498.
15. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B, André S, Crijns HJGM, Gabius H-J, Maessen J, Pinto YM: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.Circulation 2004, 110:3121–3128.
16. Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, Boersma E, Kardys I: Biomarkers of heart failure with normal ejection fraction: a systematic review.Eur J Heart Fail 2013, 15:1350–1362.
17. Schmitter D, Cotter G, Voors AA: Clinical use of novel biomarkers in heart failure: towards personalized medicine.Heart Fail Rev 2013, 19:369–381.
18. Lin Y-H, Lin L-Y, Wu Y-W, Chien K-L, Lee C-M, Hsu R-B, Chao C-L, Wang S-S, Hsein Y-C, Liao L-C, Ho Y-L, Chen M-F: The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.Clin Chim Acta 2009, 409:96–99.
19. Van den Borne SWM, Isobe S, Verjans JW, Petrov A, Lovhaug D, Li P, Zandbergen HR, Ni Y, Frederik P, Zhou J, Arbo B, Rogstad A, Cuthbertson A, Chettibi S, Reutelingsperger C, Blankesteijn WM, Smits JFM, Daemen MJAP, Zannad F, Vannan MA, Narula N, Pitt B, Hofstra L, Narula J: Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction.J Am Coll Cardiol 2008, 52:2017–2028.
20. Van den Borne SWM, Isobe S, Zandbergen HR, Li P, Petrov A, Wong ND, Fujimoto S, Fujimoto A, Lovhaug D, Smits JFM, Daemen MJAP, Blankesteijn WM, Reutelingsperger C, Zannad F, Narula N, Vannan MA, Pitt B, Hofstra L, Narula J: Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.JACC Cardiovasc Imaging 2009, 2:187–198.
21. Margadant C, van den Bout I, van Boxtel AL, Thijssen VL, Sonnenberg A: Epigenetic regulation of galectin-3 expression by β1 integrins promotes cell adhesion and migration.J Biol Chem 2012, 287:44684–44693.
22. Arias T, Chen J, Fayad ZA, Fuster V, Hajjar RJ, Chemaly ER: Comparison of echocardiographic measurements of left ventricular volumes to full volume magnetic resonance imaging in normal and diseased rats.J Am Soc Echocardiogr 2013, 26:910–918.
23. John CM, Leffler H, Kahl-Knutsson B, Svensson I, Jarvis GA: Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer.Clin Cancer Res 2003, 9:2374–2383.
24. Verjans JWH, Lovhaug D, Narula N, Petrov AD, Indrevoll B, Bjurgert E, Krasieva TB, Petersen LB, Kindberg GM, Solbakken M, Cuthbertson A, Vannan MA, Reutelingsperger CPM, Tromberg BJ, Hofstra L, Narula J: Noninvasive imaging of angiotensin receptors after myocardial infarction.JACC Cardiovasc Imaging 2008, 1:354–362.
25. Dilsizian V, Zynda TK, Petrov A, Ohshima S, Tahara N, Haider N, Donohue A, Aras O, Femia FJ, Hillier SM, Joyal JL, Wong ND, Coleman T, Babich JW, Narula J: Molecular imaging of human ACE-1 expression in transgenic rats.JACC Cardiovasc Imaging 2012, 5:409–418.
26. Montes GS, Nicolelis MA, Brentani-Samaia HP, Furuie SS: Collagen fibril diameters in arteries of mice. A comparison of manual and computer-aided morphometric analyses.Acta Anat (Basel) 1989, 135:57–61.
27. Rich LWP: Collagen and picrosirius red staining: a polarized light assessment of fibrillar hue and spatial distribution.Braz J morphol Sci 2005, 135:97–104.
28. Vaidyanathan G, Zalutsky MR: Protein radiohalogenation: observations on the design of N-succinimidyl ester acylation agents.Bioconjug Chem 1990, 1:269–273.
29. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG: The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction.J Mol Cell Cardiol 2010, 48:504–511.
30. Ahmad T, Felker GM: Galectin-3 in heart failure: more answers or more questions?J Am Heart Assoc 2012, 1:e004374.
31. Yu L, Ruifrok WPT, Meissner M, Bos EM, van Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IJ, Koerts JA, van Veldhuisen DJ, Bank RA, van Gilst WH, Silljé HHW, de Boer RA: Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.Circ Heart Fail 2013, 6:107–117.
32. MacKinnon AC, Liu X, Hadoke PW, Miller MR, Newby DE, Sethi T: Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice.Glycobiology 2013, 23:654–663.